Breaking News
Get 50% Off 0
🏄 Grow your portfolio even on vacation with InvestingPro | Summer Sale 50% OFF
CLAIM SALE
Close

Tenaya Therapeutics Inc (TNYA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Tenaya Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.861 +0.104    +13.74%
13/08 - Closed. Currency in USD
Pre Market
0.863
+0.002
+0.232%
9:24:07 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 5,604,553
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.782 - 0.900
Tenaya Therapeutics 0.861 +0.104 +13.74%

Tenaya Therapeutics Inc Company Profile

 
Get an in-depth profile of Tenaya Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

97

Equity Type

ORD

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Contact Information

Address 171 Oyster Point Boulevard Suite 500
South San Francisco, 94080
United States
Phone 650 825 6990
Fax -

Top Executives

Name Age Since Title
David V. Goeddel 72 2016 Independent Chairman of the Board
Jeffrey T. Walsh 58 2020 Independent Director
Timothy Hoey 65 2017 Member of Scientific Advisory Board
Eric N. Olson - - Scientific Founder & Member of Scientific Advisory Board
Faraz Ali 51 2018 CEO, Interim Principal Financial Officer & Director
Deepak Srivastava 58 2016 Scientific Founder, Chairman of Scientific Advisory Board & Director
June H. Lee 59 2021 Independent Director
Jonathan S. Weissman - - Member of Scientific Advisory Board
Catherine Stehman-Breen 62 2020 Independent Director
R. Sanders Williams 76 2016 Independent Director
Mark A. Kay 67 - Member of Scientific Advisory Board
Douglas L. Mann - - Member of Scientific Advisory Board
Amy L. Burroughs 55 2022 Independent Director
Karah Herdman Parschauer 47 2021 Independent Director
Christine Edry Seidman - 2023 Member of Scientific Advisory Board
Alexander Marson - 2023 Member of Scientific Advisory Board
Barry J. Byrne - 2024 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TNYA Comments

Write your thoughts about Tenaya Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email